Photogen Technologies is moving quickly to solidify its ultrasound contrast program. A day after announcing its acquisition of the ultrasound contrast assets of Alliance Pharmaceutical, the New Hope, PA-based vendor said it has sued Amersham Health and related Amersham entities to protect its newly-acquired patent portfolio.
The complaint, filed in the U.S. District Court in New Jersey, alleges that Amersham and related entities infringe -- principally with its Optison agent-- on seven patents owned by Photogen. Photogen is also seeking a declaration that the claims of 14 Amersham patents are invalid and are not infringed by Photogen's Imagent (formerly Imavist) agent.
Photogen and Alliance Pharmaceutical are seeking damages, an injunction against Amersham, a declaratory judgment, and other relief, according to Photogen.
By AuntMinnie.com staff writersJune 23, 2003
Related Reading
Alliance imaging assets acquired by Photogen, June 19, 2003
Alliance revenues sink, May 16, 2003
Alliance to sell off Imagent assets, November 25, 2002
Photogen reports success with CT plaque imaging, March 19, 2002
Copyright © 2003 AuntMinnie.com
